Cell viability in SiHa cervical cancer cells

Cell viability in SiHa cervical cancer cells is a phenotypic biological endpoint used to quantify the survival and metabolic health of the SiHa cell line, a human cervical squamous cell carcinoma model (ATCC HTB-35). SiHa cells are notable for containing integrated Human Papillomavirus 16 (HPV-16) genomes, making them a standard tool for investigating HPV-driven oncogenesis and evaluating potential therapeutic interventions (Friedl et al., 1970). This parameter is not a discrete molecular target, such as a specific protein or receptor, but rather a measure of the collective physiological response of the cell population to external stimuli. It is typically assessed using metabolic assays like MTT, XTT, or CCK-8, which provide a readout of drug efficacy in terms of growth inhibition or cytotoxicity (NIH Assay Guidance Manual). In drug discovery, monitoring SiHa cell viability allows for the screening of compounds that may induce apoptosis or cell cycle arrest, providing a preliminary assessment of anticancer activity. While essential for preclinical research, results from these assays require further validation to identify the specific molecular mechanisms involved, such as the inhibition of viral oncoproteins E6 and E7 or the activation of tumor suppressors like p53 and pRb.

Other names

SiHa cell survivalSiHa cell proliferationSiHa cytotoxicity assayCervical cancer cell growth

Not applicable (Phenotypic measurement)